JP2022544785A5 - - Google Patents

Info

Publication number
JP2022544785A5
JP2022544785A5 JP2022509060A JP2022509060A JP2022544785A5 JP 2022544785 A5 JP2022544785 A5 JP 2022544785A5 JP 2022509060 A JP2022509060 A JP 2022509060A JP 2022509060 A JP2022509060 A JP 2022509060A JP 2022544785 A5 JP2022544785 A5 JP 2022544785A5
Authority
JP
Japan
Prior art keywords
seq
modified
sequence
polypeptide
polypeptide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022509060A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544785A (ja
JP7783164B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/046244 external-priority patent/WO2021030633A1/en
Publication of JP2022544785A publication Critical patent/JP2022544785A/ja
Publication of JP2022544785A5 publication Critical patent/JP2022544785A5/ja
Priority to JP2025203501A priority Critical patent/JP2026032136A/ja
Application granted granted Critical
Publication of JP7783164B2 publication Critical patent/JP7783164B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022509060A 2019-08-13 2020-08-13 改変インターロイキン2受容体ベータアゴニスト Active JP7783164B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025203501A JP2026032136A (ja) 2019-08-13 2025-11-26 改変インターロイキン2受容体ベータアゴニスト

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962886148P 2019-08-13 2019-08-13
US62/886,148 2019-08-13
PCT/US2020/046244 WO2021030633A1 (en) 2019-08-13 2020-08-13 Engineered interleukin-2 receptor beta agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025203501A Division JP2026032136A (ja) 2019-08-13 2025-11-26 改変インターロイキン2受容体ベータアゴニスト

Publications (3)

Publication Number Publication Date
JP2022544785A JP2022544785A (ja) 2022-10-21
JP2022544785A5 true JP2022544785A5 (cg-RX-API-DMAC7.html) 2023-08-22
JP7783164B2 JP7783164B2 (ja) 2025-12-09

Family

ID=72243240

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022509060A Active JP7783164B2 (ja) 2019-08-13 2020-08-13 改変インターロイキン2受容体ベータアゴニスト
JP2025203501A Pending JP2026032136A (ja) 2019-08-13 2025-11-26 改変インターロイキン2受容体ベータアゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025203501A Pending JP2026032136A (ja) 2019-08-13 2025-11-26 改変インターロイキン2受容体ベータアゴニスト

Country Status (8)

Country Link
US (1) US20230002466A1 (cg-RX-API-DMAC7.html)
EP (1) EP4013774A1 (cg-RX-API-DMAC7.html)
JP (2) JP7783164B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220044534A (cg-RX-API-DMAC7.html)
CN (1) CN114787182A (cg-RX-API-DMAC7.html)
AU (1) AU2020329290A1 (cg-RX-API-DMAC7.html)
CA (1) CA3147677A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021030633A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220140514A (ko) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 변형된 il-2 폴리펩타이드 및 그의 용도
BR112022017656A2 (pt) * 2020-03-05 2022-10-18 Univ Leland Stanford Junior Variantes de il-2 concebidas
EP4251187A4 (en) 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
IL304365B2 (en) 2021-03-31 2025-04-01 Hanmi Pharmaceutical Co Ltd A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof
EP4373848A2 (en) * 2021-07-22 2024-05-29 University of Dundee Therapeutic muteins
CN113603791A (zh) * 2021-08-11 2021-11-05 厦门目青股权投资合伙企业(有限合伙) 一种融合蛋白及其应用
WO2023220597A1 (en) * 2022-05-10 2023-11-16 Elpis Biopharmaceuticals Engineered interleukin-2 receptor beta reduced-binding agonist
WO2025010341A2 (en) * 2023-07-05 2025-01-09 The Trustees Of Dartmouth College Cytokine hybrid proteins and methods related thereto
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
IL131016A (en) 1997-01-21 2004-12-15 Gen Hospital Corp Selection of proteins using RNA-protein blends
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
JP2009542592A (ja) * 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Il−2媒介性免疫応答の有効性を高める組成物および方法
WO2012088446A1 (en) * 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
CN105440123B (zh) * 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
WO2012119093A1 (en) * 2011-03-03 2012-09-07 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
CN109608550B (zh) * 2012-12-05 2020-09-11 生控基因疫苗股份有限公司 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
JP6592505B2 (ja) * 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
WO2016126719A1 (en) * 2015-02-03 2016-08-11 Jyant Technologies, Inc. Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
TWI833684B (zh) * 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體(car)、組合物及其使用方法
US12522640B2 (en) * 2018-07-24 2026-01-13 BioNTech SE IL2 agonists

Similar Documents

Publication Publication Date Title
Nuñez-Prado et al. The coming of age of engineered multivalent antibodies
CN107922486B (zh) 异源二聚体多特异性抗体形式
Morris et al. Advances in interleukin 2 receptor targeted treatment
Stork et al. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G
AU2018280683B2 (en) Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA
JP2023123649A5 (cg-RX-API-DMAC7.html)
JP2024099850A5 (cg-RX-API-DMAC7.html)
JP2023504914A5 (cg-RX-API-DMAC7.html)
JP2023534636A5 (cg-RX-API-DMAC7.html)
JP2013529070A5 (cg-RX-API-DMAC7.html)
JP2022521937A5 (cg-RX-API-DMAC7.html)
JP2017504577A5 (cg-RX-API-DMAC7.html)
AU2017361846A1 (en) T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
JP2016527314A5 (cg-RX-API-DMAC7.html)
JP2017504578A5 (cg-RX-API-DMAC7.html)
JP2024511465A5 (cg-RX-API-DMAC7.html)
CN105229036A (zh) 在疏水性相互作用位点内引入了静电相互作用的蛋白及其制备方法
JP2023553694A5 (cg-RX-API-DMAC7.html)
JP2025530888A5 (cg-RX-API-DMAC7.html)
JP2019505565A5 (cg-RX-API-DMAC7.html)
Acheampong Bispecific antibody (bsAb) construct formats and their application in cancer therapy
JP2024531346A5 (cg-RX-API-DMAC7.html)
JP2015012869A5 (cg-RX-API-DMAC7.html)
Asano et al. Anti‐EGFR scFv tetramer (tetrabody) with a stable monodisperse structure, strong anticancer effect, and a long in vivo half‐life
WO2003033653B1 (en) Affinity enhancement agents